Kodiak Sciences Inc KOD

$99.87 +5.61 (5.95%)

Valuation

Market cap
5,724,286,000
Revenue TTM
$0
Net income TTM
$-229,970,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,732,479
Avg volume
1,832,278
Day's range
$93.70 – $100.33
Shares out
62,849,000
Stochastic %K
82%
Beta
2.03
Analysts
Strong Sell
Price target
$116.67

Price

Company profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical stu...

Show more

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 281 0850
Website
https://kodiak.com
Address
1250 Page Mill Road, Palo Alto, United States

Latest news

Stocktwits

Loparla Oct 9, 9:49 PM
$KOD smells like a $100 buyout… 🤔
0 replies
Stekli27 Oct 9, 9:45 PM
$KOD Funny how the bears keep spamming the same dilution story while completely ignoring the pipeline. 😂 Five positive Phase 3 trials supporting Zenkuda’s planned BLA, KSI-101 with first-in-class potential in MESI, and KSI-501 still offering significant upside. Dilution? Sure, it’s possible. But remember December? $184M raised, with Baker Bros buying a substantial chunk. This isn’t a one-trick pony anymore. If Kodiak delivers another successful drug, today’s valuation could look cheap in hindsight. Keep spamming. Some of us are investing beyond tomorrow’s candle. 😎
0 replies
hp12349472 Oct 9, 9:43 PM
$KOD 2nd presentation happening now?
0 replies
Justsayng Oct 9, 9:40 PM
$KOD $50 dollars by the end of October. Nothing new today from this presentation. Same O stuff! No revs No money No buyout No fda approval yet…. Overbought and overhyped Insttituiyions will start dumping next week I have no doubt about it
0 replies
hp12349472 Oct 9, 9:40 PM
$KOD so what happened, any update?
0 replies
tymerz Oct 9, 9:36 PM
$KOD I guess the rich Baker Brothers didn't want to spend any money on being a sponsor? With all they claim to have invested here and the claim of Phase 3? Sus!!!
0 replies
tymerz Oct 9, 9:34 PM
$KOD And the bottom half as well. Not hiding anything here.
2 replies
tymerz Oct 9, 9:34 PM
$KOD Not even a sponsor. Oh yeah, because they have ZERO money!!! Straight from the event on YouTube.
1 replies